XOMA Royalty (XOMA) Liabilities and Shareholders Equity (2010 - 2026)
XOMA Royalty (XOMA) reported Liabilities and Shareholders Equity of $271.9 million for Q1 2026, up 27.78% on a YoY basis from $212.8 million in Q1 2025, and little changed sequentially from $272.7 million in Q4 2025.
XOMA Royalty (XOMA) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
XOMA Royalty (XOMA) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $271.9 million in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 27.78% year-over-year to $271.9 million; the trailing twelve-month figure through Mar 2026 stood at $768.0 million (down 14.73% YoY), and the FY2025 full-year result was $272.7 million, up 23.24% from the prior year.
- Liabilities and Shareholders Equity was little changed at $271.9 million in Q1 2026, from $272.7 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $272.7 million in Q4 2025 to a low of $124.1 million in Q3 2023.
- A 5-year average of $194.1 million and a median of $216.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity fell 18.52% in 2023 and surged 93.6% in 2024, its largest moves.
- Tracing XOMA's Liabilities and Shareholders Equity over 5 years: stood at $140.4 million in 2022, then jumped by 66.9% to $234.3 million in 2023, then declined by 5.56% to $221.3 million in 2024, then advanced by 23.24% to $272.7 million in 2025, then dropped by 0.31% to $271.9 million in 2026.
- Business Quant data shows XOMA's Liabilities and Shareholders Equity at $271.9 million in Q1 2026, $272.7 million in Q4 2025, and $223.5 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 78.88 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.55 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 39.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.25 Bn |
| 10 | XOMA Royalty | 478.42 Mn | 412.34 Mn | - | 271.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 271.86 Mn |
| Dec 31, 2025 | 272.70 Mn |
| Jun 30, 2025 | 223.46 Mn |
| Mar 31, 2025 | 212.75 Mn |
| Dec 31, 2024 | 221.28 Mn |
| Sep 30, 2024 | 223.34 Mn |
| Jun 30, 2024 | 243.28 Mn |
| Mar 31, 2024 | 219.42 Mn |
| Dec 31, 2023 | 234.30 Mn |
| Sep 30, 2023 | 124.09 Mn |
| Jun 30, 2023 | 125.66 Mn |
| Mar 31, 2023 | 133.66 Mn |
| Dec 31, 2022 | 140.38 Mn |
| Sep 30, 2022 | 146.13 Mn |
| Jun 30, 2022 | 154.22 Mn |
| Mar 31, 2022 | 159.16 Mn |
| Dec 31, 2021 | 166.56 Mn |
| Sep 30, 2021 | 130.50 Mn |
| Jun 30, 2021 | 135.75 Mn |
| Mar 31, 2021 | 119.89 Mn |